Deutsch Barry M. 4
4 · XERIS PHARMACEUTICALS INC · Filed Jun 27, 2018
Insider Transaction Report
Form 4
Deutsch Barry M.
Chief Financial Officer
Transactions
- Conversion
Common Stock
2018-06-25+2,238→ 23,292 total - Conversion
Series C Preferred Stock
2018-06-25−3,987→ 0 total→ Common Stock (2,238 underlying)
Footnotes (1)
- [F1]Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date.